Seattle, United States
HDT Bio, a biotechnology company founded in 2018 and headquartered in the United States, is making strides in the fields of biopharma and pharmaceuticals. With the slogan "Immune Therapy For All", the company is pioneering next-generation approaches to harness the immune system's ability to combat cancer and infectious diseases such as SARS-CoV-2.
The company is advancing multiple product candidates from its proprietary platforms, including the promising LION™ technology. Their products are engineered to be cost-effective and act as complements to existing immunotherapies.
Most recently, HDT Bio secured a $1.00M grant investment on 01 October 2023, underscoring growing investor confidence. The company's strong comprehensive compensation plan for employees and its commitment to diversity and inclusion indicate a sustainable business ethos. As HDT Bio continues to enhance its technology, it holds significant potential to address unmet medical needs on a wide scale.
